ES2139759T3 - Antagonistas de citoquina. - Google Patents

Antagonistas de citoquina.

Info

Publication number
ES2139759T3
ES2139759T3 ES94930818T ES94930818T ES2139759T3 ES 2139759 T3 ES2139759 T3 ES 2139759T3 ES 94930818 T ES94930818 T ES 94930818T ES 94930818 T ES94930818 T ES 94930818T ES 2139759 T3 ES2139759 T3 ES 2139759T3
Authority
ES
Spain
Prior art keywords
cytokine antagonists
receptor component
antagonsists
cntf
extracellular domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94930818T
Other languages
English (en)
Other versions
ES2139759T5 (es
Inventor
Neil Stahl
Economides
George D Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22490270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139759(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of ES2139759T3 publication Critical patent/ES2139759T3/es
Application granted granted Critical
Publication of ES2139759T5 publication Critical patent/ES2139759T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROTEINAS HETERODIMERICAS QUE COMPRENDEN UNA ESPECIFICIDAD {AL} SOLUBLE QUE DETERMINA UN COMPONENTE RECEPTOR DE LA CITOQUINA, Y EL DOMINIO EXTRACELULAR DE UN COMPONENTE {BE}-RECEPTOR Y QUE FUNCIONAN COMO ANTAGONISTAS DEL CNTF Y DE IL-6.
ES94930818T 1993-10-20 1994-10-19 Antagonistas de citoquina. Expired - Lifetime ES2139759T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US140222 1993-10-20
US08/140,222 US5470952A (en) 1993-10-20 1993-10-20 CNTF and IL-6 antagonists

Publications (2)

Publication Number Publication Date
ES2139759T3 true ES2139759T3 (es) 2000-02-16
ES2139759T5 ES2139759T5 (es) 2007-11-16

Family

ID=22490270

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94930818T Expired - Lifetime ES2139759T5 (es) 1993-10-20 1994-10-19 Antagonistas de citoquina.

Country Status (15)

Country Link
US (2) US5470952A (es)
EP (1) EP0726954B2 (es)
JP (1) JP3961562B2 (es)
CN (1) CN1138350A (es)
AT (1) ATE187982T1 (es)
AU (1) AU679579B2 (es)
CA (1) CA2173846C (es)
DE (1) DE69422304T3 (es)
DK (1) DK0726954T4 (es)
ES (1) ES2139759T5 (es)
GR (1) GR3032777T3 (es)
IL (1) IL111324A0 (es)
PT (1) PT726954E (es)
WO (1) WO1995011303A1 (es)
ZA (1) ZA948242B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
AUPN024994A0 (en) * 1994-12-23 1995-01-27 Ludwig Institute For Cancer Research Assay and peptides for use therein
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
SE9701010D0 (sv) 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
EP1047781B1 (en) 1998-01-23 2004-07-28 Immunex Corporation Il-18 receptors
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083949B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6864359B1 (en) * 1999-02-11 2005-03-08 Xencor Structure-based screening techniques for drug discovery
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
DE60041393D1 (de) * 1999-03-11 2009-03-05 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
US6682739B1 (en) * 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
AU777634B2 (en) * 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
WO2001016166A2 (en) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
AR025984A1 (es) * 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
WO2002064021A2 (en) * 2001-02-12 2002-08-22 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity
US6864047B2 (en) * 2001-03-29 2005-03-08 Mayo Foundation For Medical Education And Research IL1-β: a new target for myeloma therapy
EP1382965B1 (en) * 2001-04-23 2005-11-30 Eiken Kagaku Kabushiki Kaisha Analysis method using reporter (label) intermolecular interaction
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
JP2005514913A (ja) * 2001-08-22 2005-05-26 へリックス バイオファーマ コーポレイション 内在性タンパク質の発現、精製および検出のための、方法およびデバイス
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
WO2004019866A2 (en) 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
JP4989850B2 (ja) * 2002-10-25 2012-08-01 アメリカ合衆国 ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
FI20031050L (fi) * 2003-07-09 2005-01-10 Valtion Teknillinen Menetelmä proteiinien katkaisuun
US20050069987A1 (en) * 2003-09-30 2005-03-31 Daly Thomas J. Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007061981A2 (en) 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
TWI381850B (zh) * 2005-12-30 2013-01-11 Pharmaessentia Corp 藥物與聚合物之共軛物
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
WO2008113185A1 (en) 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
WO2010031168A1 (en) * 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
BR112019020955A2 (pt) 2017-04-07 2020-05-05 Apellis Pharmaceuticals, Inc. regimes de dosagem e composições e métodos relacionados
JP7657548B2 (ja) 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
JP2021507884A (ja) 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
CN119431579A (zh) 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法
EP3836954B1 (en) 2018-08-13 2025-05-07 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3870601A4 (en) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3255699B2 (ja) * 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists

Also Published As

Publication number Publication date
JP3961562B2 (ja) 2007-08-22
PT726954E (pt) 2000-04-28
AU7982794A (en) 1995-05-08
EP0726954B1 (en) 1999-12-22
ATE187982T1 (de) 2000-01-15
DK0726954T3 (da) 2000-05-01
US5844099A (en) 1998-12-01
AU679579B2 (en) 1997-07-03
DK0726954T4 (da) 2007-10-01
CA2173846C (en) 2009-01-27
EP0726954A1 (en) 1996-08-21
DE69422304T2 (de) 2000-05-11
HK1008346A1 (en) 1999-05-07
EP0726954B2 (en) 2007-05-30
US5470952A (en) 1995-11-28
ZA948242B (en) 1995-06-13
DE69422304D1 (de) 2000-01-27
JPH09504030A (ja) 1997-04-22
CN1138350A (zh) 1996-12-18
WO1995011303A1 (en) 1995-04-27
ES2139759T5 (es) 2007-11-16
GR3032777T3 (en) 2000-06-30
CA2173846A1 (en) 1995-04-27
DE69422304T3 (de) 2007-12-27
IL111324A0 (en) 1994-12-29

Similar Documents

Publication Publication Date Title
ATE187982T1 (de) Cytokine antagoniste
ATE309375T1 (de) Onkostatin- m rezeptor
NO952398L (no) Pyrrolpyrimidiner som CRF antagonister
DE69738841D1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
FI946005L (fi) Glysiinireseptoriantagonisteja ja niiden käyttö
MY108579A (en) Endothelin receptor antagonists
EP0667773A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS.
FI961804A7 (fi) Endoteliinireseptoriantagonistit
FI941178L (fi) 5-HT4-reseptoriantagonisteja
GR1001129B (el) Ανταγωνιστες ccκ αναλογου αμινοξεος.
ES2172535T3 (es) Antagonistas de los receptores de la endotelina.
FI933253A7 (fi) Uusia amyliiniantagonistipeptidejä ja käyttö amyliiniantagonisteina
MX9203074A (es) 4-(1h-pirrol-1-il)-imidazoles con actividad antagonista de angiotensina ii.
RU94044322A (ru) Замещенные в кольце z-амино-1,2,3,4-тетрагидронафталины и 3-аминохроманы
DK0852587T3 (da) Syntetiske peptider der inhiberer IL-6-aktivitet
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
MX9606179A (es) Agonistas y antagonistas de los receptores del acido acetilcolina nicotinico de insectos para el control de endoparasitos.
BR9408265A (pt) Antagonistas de receptor de c5a não tendo substancialmente nenhuma atividade de antagonista
MX9203582A (es) Peptidos y composiciones farmaceuticas con actividad agonista y antagonista de la hormona de glicoproteina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 726954

Country of ref document: ES